DARYL T LAU
Affiliation: Harvard University
- Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patientsDaryl T Y Lau
Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Hepatology 47:799-809. 2008..CONCLUSION: These results indicate that HCV can transiently trigger IRF-3 activation during virus spread and that in chronic HCV, IRF-3 activation within infected hepatocytes occurs but is limited...
- Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infectionDaryl T Y Lau
Liver Center, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 144:402-413.e12. 2013..We used a systems biology approach to evaluate the acute response of patients with chronic hepatitis C to IFN-α therapy...
- Current status of antiviral therapy for hepatitis BDaryl T Y Lau
Associate Professor of Medicine, Harvard Medical School HMS, Director of Translational Liver Research, Beth Israel Deaconess Medical Center, HMS Liver Center, Division of Gastroenterology, Department of Medicine, 110 Francis Street, Suite 4A, Boston, MA 02215
Therap Adv Gastroenterol 1:61-75. 2008..It is equally important to conduct a well designed, prospective natural history study to identify predictors of disease progression. This will accurately guide treatment strategy for this important disease...
- Hepatitis B: the pathway to recovery through treatmentF Blaine Hollinger
Department of Medicine, Eugene B Casey Hepatitis Research Center and Diagnostic Laboratory, Baylor College of Medicine, One Baylor Plaza, BCM 385, Houston, TX 77030 3498, USA
Gastroenterol Clin North Am 35:425-61, x. 2006..Prevention remains the most effective strategy in the global management of hepatitis B virus. Universal immunization programs prevent hepatitis B virus transmission and circumvent acute and chronic infection...
- Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effectorKarla J Helbig
Infectious Diseases Laboratories and Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
Hepatology 42:702-10. 2005..Furthermore, ISG viperin has anti-HCV activity in vitro; we postulate that viperin, along with other ISGs, acts to limit HCV replication...
- Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosisDaryl T Y Lau
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 0764, USA
Hepatology 42:273-81. 2005..Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index/html)...
- Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infectionYueh Ming Loo
Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Proc Natl Acad Sci U S A 103:6001-6. 2006..HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice...
- The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis CNed Snyder
Department of Internal Medicine, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, Texas 77555 0764, United States
Clin Chim Acta 381:119-23. 2007....
- Racial Differences in IFN Transcriptional ResponseDaryl Lau; Fiscal Year: 2007..between early virological responders and non-responders will lead to a better understanding of host pathways involved in the suppression of hepatitis C virus replication and the induction of a sustained virological response to therapy ..
- Racial Differences in IFN Transcriptional ResponseDaryl Lau; Fiscal Year: 2009..between early virological responders and non-responders will lead to a better understanding of host pathways involved in the suppression of hepatitis C virus replication and the induction of a sustained virological response to therapy ..